Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients

Acta Neurologica Scandinavica

Volumn 129, Issue 1, 2014, Pages

  Merola, A ^a   Zibetti, M ^a   Rizzone, M G ^a   Troiano, M ^a   Artusi, C A ^a   Angrisano, S ^a   Cocito, D ^a   Lopiano, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Neuropathies; Neurophysiology; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHYLMALONIC ACID;

ACTION POTENTIAL; ADULT; AGED; AMINO ACID BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; DRUG DOSE INCREASE; ELECTROPHYSIOLOGY; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; MALE; METHYLMALONIC ACIDEMIA; NERVE CONDUCTION; NOTE; PARKINSON DISEASE; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

NEUROPATHIES; NEUROPHYSIOLOGY; PARKINSON'S DISEASE;

ACTION POTENTIALS; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; INTESTINAL ABSORPTION; LEVODOPA; MALE; MIDDLE AGED; NEURAL CONDUCTION; PARKINSONIAN DISORDERS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; REACTION TIME; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 84888873085     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12164     Document Type: Note

References (13)

1. Toth C, Breithaupt K, Ge S et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010;68:28-36.
2. Rajabally YA, Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011;77: 1947-50.
3. Antonini A, Isaias IU, Canesi M et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9.
4. Manca D, Cossu G, Murgia D et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009;24:2293-4.
5. Urban PP, Wellach I, Faiss S et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010;25:1748-52.
6. Klostermann F, Jugel C, Müller T, Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012;119:369-72.
7. Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord 2009;15(Suppl3):S233-6.
8. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information, 1987;153-63.
9. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006;77:973-6.
10. Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-9.
11. Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000;54:943-9.
12. Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice, III edition. New York, USA: Oxford University Press, 2001.
13. Pålhagen SE, Dizdar N, Hauge T et al. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 2012; 126:29-33.